Ron Finklestien

Exciting Developments in the Mineral and Recycling Sectors Exciting Developments in the Mineral and Recycling Sectors

Foremost Lithium Receives Grant for Zoro Project Foremost Lithium Resource & Technology Ltd. FMST announced that it received its third $300,000 grant from the Manitoba Mineral Development Fund to support its 7,500-meter diamond drill program at its Zoro Lithium...

Equifax Named Top Pick For 2024 By Needham, Price Target Raised On Expected Mortgage Rate Tailwinds Equifax’s Momentum Soars: Needham Names Them Top Pick for...

Needham analyst Kyle Peterson maintains Equifax Inc EFX with a Buy and raises the price target from $230 to $305. Kyle Peterson, a discerning analyst at Needham, has crowned Equifax Inc as his Top Pick for 2024, dethroning the...

TotalEnergies (TTE) Starts Producing From Mero Field Second Phase Exciting Development: TotalEnergies (TTE) Commences Production in Mero Field’s Second Phase

TotalEnergies SE TTE has announced the commencement of production from the second development phase of the Mero field, situated on the Libra block over 112 miles (180 kilometers) off the coast of...

Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development Atai’s $50 Million Investment in Beckley Psytech’s Psychedelics Development

Biopharma and resources-pooling company Atai Life Sciences ATAI has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing...

Rare December Stock Selections from 34 Analysts Rare December Stock Selections from 34 Analysts

December saw a recent market surge even higher, with the S&P 500 notching gains of nearly +14% over the final 2 months of 2023. The question remains: are...

M-tron (MPTI) Hits 52-Week High: Here’s What’s Driving...

M-tron Industries, Inc. (MPTI) reached a new 52-week high of $41.62 on Jan 3. The stock pulled back to end the trading session at $36.23, down 1.5% from the previous...

Investors Cheer Positive Results in Atai Life Sciences MDMA Study Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD...

Biopharma firm Atai Life Sciences ATAI has announced the positive outcomes of a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, developed for the potential treatment of PTSD. Assessing EMP-01's safety, tolerability, pharmacokinetics (PK) and pharmacodynamics...